HCW Biologics Inc.|4Jun 2, 4:16 PM ET

Jiao Jin-an 4

4 · HCW Biologics Inc. · Filed Jun 2, 2022

Form 4

Period: 2022-05-31

VP of Development

Transactions

Exercise/Conversion
Common Stock
2022-05-31$0.21/sh+1,714$360→ 45,141 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-05-31−12,856→ 18,001 total
Exercise: $0.14Exp: 2029-05-29→ Common Stock (12,856 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-05-31−1,714→ 6,857 total
Exercise: $0.21Exp: 2030-12-22→ Common Stock (1,714 underlying)
Exercise/Conversion
Common Stock
2022-05-31$0.14/sh+12,856$1,800→ 43,427 total

Footnotes (2)

[F1]These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023.
[F2]20% of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024.

Documents

1 file